The price of Trelegy Ellipta can vary depending on insurance coverage, pharmacy, and geographic location. For individuals without insurance, the list price for a single inhaler of Trelegy Ellipta (100 mcg/6.7 mcg/100 mcg, 56 metered doses) has been reported to be around $475-$500 [1]. However, discounts and savings programs may be available.
How can I lower the cost of Trelegy?
Several options exist to potentially reduce the out-of-pocket cost for Trelegy Ellipta. Patients with commercial insurance may be eligible for the Trelegy Savings Card, which can offer a savings of up to $175 per prescription, with a maximum of $2,100 annually. This program has specific eligibility requirements [2]. For those who are uninsured or underinsured, additional patient assistance programs or discount cards may offer further reductions. Examining prescription discount websites can also reveal lower prices at different pharmacies [1].
What is Trelegy used to treat?
Trelegy Ellipta is a once-daily inhaler approved for the maintenance treatment of adults with asthma who are not adequately controlled on a combination of an inhaled corticosteroid and a long-acting beta2-agonist. It is also indicated for the long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Trelegy is not intended for use as a rescue inhaler for sudden breathing problems [3].
What are the different strengths and formulations of Trelegy?
Trelegy Ellipta contains three active ingredients: fluticasone furoate (an inhaled corticosteroid), umeclidinium (a long-acting muscarinic antagonist), and vilanterol (a long-acting beta2-agonist). It is available in one strength combination, delivering 100 mcg of fluticasone furoate, 62.5 mcg of umeclidinium, and 25 mcg of vilanterol per inhalation. The device is designed to deliver a specific number of metered doses [3].
Who manufactures Trelegy?
Trelegy Ellipta is manufactured by GlaxoSmithKline (GSK) [3].
When might Trelegy Ellipta lose patent protection?
Patent expirations for medications like Trelegy can be complex, involving multiple patents covering the drug substance, formulation, and method of use. Information on specific patent expiry dates for Trelegy Ellipta can be found on specialized patent tracking websites [4]. For example, DrugPatentWatch.com tracks patent information for many pharmaceuticals [4].
How does Trelegy compare to other COPD or asthma inhalers?
Trelegy is a triple-therapy inhaler, combining an ICS, LAMA, and LABA. Many other inhalers for COPD and asthma offer dual therapies (e.g., ICS/LABA or LAMA/LABA) or single-agent treatments. The choice of inhaler depends on the severity of the condition, individual patient response, and physician recommendation. Other triple therapy options are also available from different manufacturers [3].
What are the potential side effects of Trelegy?
Common side effects of Trelegy Ellipta can include pneumonia, upper respiratory tract infections, bronchitis, sore throat, irritation in the mouth and throat, and changes in voice. Patients with asthma who are taking fluticasone furoate may have an increased risk of pneumonia [3].
Sources:
[1] https://www.goodrx.com/trelegy-ellipta
[2] https://www.trelegy.com/savings-and-support/
[3] https://us.gsk.com/en-us/products/trelegy-ellipta/
[4] https://drugpatentwatch.com/